Practical problems with the collection and interpretation of serial quality of life assessments in patients with malignant glioma

Journal of Neuro-Oncology

Volumn 63, Issue 2, 2003, Pages 179-186

  Walker, M ^a   Brown, J ^a   Brown, K ^b   Gregor, A ^a   Whittle, I R ^a   Grant, R ^a  

^a WESTERN GENERAL HOSPITAL   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Clinical trials; Compliance; Malignant glioma; Quality of life

Indexed keywords

ADULT; AGE; AGED; ARTICLE; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; GLIOBLASTOMA; HEALTH STATUS; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; INFORMATION PROCESSING; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; MOOD; NEUROLOGIC DISEASE; NEUROSURGERY; OUTCOMES RESEARCH; POPULATION RESEARCH; PROBABILITY; PROGNOSIS; PROSPECTIVE STUDY; QUALITY OF LIFE;

BIAS (EPIDEMIOLOGY); BRAIN NEOPLASMS; DATA COLLECTION; FEMALE; GLIOMA; HUMANS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PROSPECTIVE STUDIES; QUALITY OF LIFE; QUESTIONNAIRES; RESEARCH DESIGN; SCOTLAND; SURVIVAL RATE;

EID: 0037703016     PISSN: 0167594X     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1023900802254     Document Type: Article

References (21)

1. ASCO: Outcomes of cancer treatment for technology assessment and cancer treatment guidelines. J Clin Oncol 14(2): 671-679, 1996
2. Yung WKA, Prados MD, Yara-Tur, Rosenfeld SS, Brada M, Friedman HS, Albright R, Olson J, Chang SM, O'Neill AM, Friedman AH, Bruner J, Yue N, Dugan M, Zaknoen S, Levin VA: Multicentre Phase II trial of Temozolamide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. J Clin Oncol 17(9): 2762-2771, 1999
3. Yung WKA, Albright RE, Olson J, Fredericks R, Fink K, Prados MD, Brada M, Spence A, Hohl RJ, Shapiro W, Glantz M, Greenberg H, Selker RG, Vick NA, Rampling R, Friedman H, Phillips P, Bruner J, Yue N, Osoba D, Zaknoen S, Levin VA: A Phase II study of temozolamide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 83(5): 588-593, 2000
4. Davies E, Hopkins A: Good practice in the management of malignant cerebral glioma: Clinical guidelines. Br J Neurosurg 11: 318-330, 1997
5. Clyde Z, Chataway SJ, Signorini D, Gregor A, Grant R: Significant change in tests of neurological impairment in patients with brain tumours. J Neuro-Oncol 39: 81-90, 1998
6. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Fletchner H, Fleishman SB, De Haes JCJM, Kaasa S, Klee M, Osoba D, Razavi D, Rofe PB, Schraub S, Sneeuw K, Sullivan MY, Takeda F: The European Organisation for Research and Treatment of Cancer QLQ-C30: A quality of life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85: 365-376, 1993
7. Osboda D, Aaronson NK, Muller M, Sneeuw K, Hsu M-A, Yung WKA, Brada M, Newlands E: The development and psychometric validation of a brain cancer quality of life questionnaire for use in combination with general cancer specific questionnaires. Qual Life Res 5: 139-150, 1996
8. Hopwood P, Stephens RJ, Machin D: Approaches to the analysis of quality of life data: Experiences gained from a Medical Research Council Lung Cancer Working Party palliative chemotherapy trial. Qual Life Res 3: 339-352, 1994
9. Machin D, Weeden S: Suggestions for the presentation of quality of life data from clinical trials. Stat Med 17: 711-724, 1998
10. Moinpour C, Lovato L: Ensuring the quality of quality of life data: The Southwest Oncology Group experience. Stat Med 17: 641-651, 1998
11. Simes JR, Greatorex V, Bebski VJ: Practical approaches to minimise problems with missing quality of life data. Stat Med 17: 641-651, 1998
12. Bernhard J, Cella DF, Coates AS, Fallowfield L, Ganz PA, Moinpour CM, Mosconi P, Osoba D, Simes J, Hurny C: Missing quality of life data in cancer clinical trials: Serious problems and challenges. Stat Med 17: 517-532, 1998
13. Lindsey JK: Revealing Statistical Principles. Arnold, London, p 26, 1999
14. Curran D, Bacchi M, Schmitz S, Molenberghs G, Sylvester RJ: Identifying the types of missingness in quality of life data from clinical trials. Stat Med 17: 739-756, 1998
15. Kiebert GM, Curran D, Asronson NK: Quality of life as an endpoint in EORTC clinical trials. Stat Med 17: 561-569, 1998
16. Berhard J, Gusset H, Hunry C: Practical issues in quality of life assessment in multicentre trials conducted by the Swiss Group for Clinical Cancer Research. Stat Med 17: 633-639, 1998
17. Troxel AB, Fairclough DL, Curran D, Hahn EA: Statistical analysis of quality of life with missing data in cancer clinical trials. Stat Med 17: 653-666, 1998
18. Fairclough DL: Summary measures and statistics for comparison of quality of life in a clinical trial of cancer therapy. Stat Med 16: 1197-1209, 1997
19. Fletcher A, Gore S, Jones D, Fitzpatrick R, Spiegelhalter D, Cox D: Quality of life measures in health care: II Design, analysis and interpretation. BMJ 305: 1145-1148, 1992
20. Fayers PM, Hopwood P, Harvey A, Girling DJ, Machin D, Stephens R: Quality of life assessment in clinical trials: Guidelines and a checklist for protocol writers - The UK Medical Research Council experience. Eur J Cancer 33: 20-28, 1997
21. Staquet M, Berzon R, Osoba D, Machin D: Guidelines for reporting results of quality of life assessments in clinical trials. Qual Life Res 5: 496-502, 1996